Tick-Borne Encephalitis Vaccines
Inactivated viral vaccines for TBE prevention in endemic regions
This page catalogs 3 tick-borne encephalitis vaccine products spanning the first US-licensed TBE vaccine and established European formulations. TBE vaccination has been routine in endemic European countries for decades, with the 2021 US licensure of Ticovac representing the first FDA-approved option for American travelers to endemic regions.
Last updated: April 2026.
Tick-Borne Encephalitis Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Ticovac | Tick-borne encephalitis vaccine | Pfizer | Inactivated viral | FDA Licensed, 2021 | First US-licensed TBE vaccine |
| FSME-Immun | TBE vaccine | Pfizer (Baxter legacy) | Inactivated viral | EMA Authorized | European TBE; same product as Ticovac |
| Encepur | TBE vaccine | GSK (Novartis legacy) | Inactivated viral | EMA Authorized | European TBE vaccine |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.